Key Insights The projected fair value for Climb Bio is US$9.09 based on 2 Stage Free Cash Flow to Equity Climb ...

Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., ...